Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
DNA damage
Biotech
Artios Pharma widens clinical ambitions with $115M series D
The biotech will use the funds to extend its clinical ambitions for its pipeline of DNA-damage-response-inhibiting cancer prospects.
Zoey Becker
Nov 17, 2025 8:00am
Rakovina deepens AI focus with collab to select cancer targets
Sep 17, 2024 9:20am
Don't junk DNA as study shows new role in brain disease
Sep 30, 2022 3:25pm
Fighting drug-resistant cancer by blocking an escape route
Jan 5, 2022 8:35am
How strange DNA structures could inspire new cancer drugs
Dec 29, 2021 4:34am
Injured tumor cells activate I-O drugs in cancer models
Oct 19, 2021 2:00pm
